February 21, 2026American Journal of Hematology1 citationsOpen Access
TP53 Mutations and Circulating Blasts ≥ 20% Are the Primary Determinants of Survival in Accelerated/Blast‐Phase Myeloproliferative Neoplasms Treated With Frontline Venetoclax Plus Hypomethylating Agent
To determine the factors influencing survival outcomes in patients with accelerated or blast-phase myeloproliferative neoplasms treated with venetoclax and hypomethylating agents.
Analysis of survival outcomes among 82 patients at Mayo Clinic with MPN-BP/AP.
Evaluation of TP53 mutations present in patients.
Assessment of circulating blasts levels in patients.
Patients with TP53 mutations had significantly lower survival rates.
Elevated circulating blasts (≥20%) were associated with poorer survival outcomes.
Combined analysis reveals that both TP53 mutations and circulating blasts are critical determinants of survival.
Abstract
Survival outcome among 82 Mayo Clinic patients with blast/accelerated phase myeloproliferative neoplasm (MPN-BP/AP).